Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29 Novembro 2024 - 6:10PM
Business Wire
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in
precision genetic medicine for rare diseases, granted equity awards
on November 29, 2024 (the “Grant Date”) that were previously
approved by the Compensation Committee of its Board of Directors
under Sarepta’s 2024 Employment Commencement Incentive Plan, as a
material inducement to employment to 14 individuals hired by
Sarepta in November 2024. The equity awards were approved in
accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received in the aggregate 8,040 restricted stock
units (“RSUs”). One-fourth of the RSUs will vest yearly on each
anniversary of the Grant Date, such that the RSUs granted to each
employee will be fully vested on the fourth anniversary of the
Grant Date, in each case, subject to each such employee’s continued
employment with Sarepta on such vesting date. Employees did not
receive options to purchase shares of Sarepta’s common stock.
About Sarepta Therapeutics Sarepta is on an urgent mission:
engineer precision genetic medicine for rare diseases that
devastate lives and cut futures short. We hold leadership positions
in Duchenne muscular dystrophy (DMD) and limb-girdle muscular
dystrophies (LGMDs), and we currently have more than 40 programs in
various stages of development. Our vast pipeline is driven by our
multi-platform Precision Genetic Medicine Engine in gene therapy,
RNA and gene editing. For more information, please visit
www.sarepta.com or follow us on LinkedIn, X (formerly Twitter),
Instagram and Facebook.
Internet Posting of Information We routinely post information
that may be important to investors in the 'For Investors' section
of our website at www.sarepta.com. We encourage investors and
potential investors to consult our website regularly for important
information about us.
Source: Sarepta Therapeutics, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241129198597/en/
Investor Contact: Ian Estepan, 617-274-4052
iestepan@sarepta.com
Media Contact: Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com
Sarepta Therapeutics (NASDAQ:SRPT)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Sarepta Therapeutics (NASDAQ:SRPT)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024